- Home
- A-Z Publications
- Current Drug Targets
- Previous Issues
- Volume 11, Issue 8, 2010
Current Drug Targets - Volume 11, Issue 8, 2010
Volume 11, Issue 8, 2010
-
-
Editorial [Hot topic: MicroRNAs: from Basic Regulation Towards Therapeutic Approaches - Passion, Caution and Patience Required (Guest Editor: Dr. Thomas Thum)]
By Thomas ThumWorldwide research activities about the role of small regulatory RNA molecules, especially microRNAs, have been exploded and promise development of more mechanistic-orientated molecular therapies of an array of diseases. One of the most important characteristics of miRNAs may be the fact the miRNAs not only regulate single genes but fine-tune complete pathways of often co-ordinately acting genes. In this Read More
-
-
-
MicroRNA Regulation in Cardiovascular Disease
Authors: P.A. da Costa Martins, S. Leptidis, K. Salic and L.J. De WindtThe molecular biology dogma that DNA replicates its genetic information within nucleotide sequences and transcribes it to RNA where it codes for the generation of mRNA, failed to consider a significant part of the genetic code. Although it has been generally assumed that most genetic information is executed by proteins, recent evidence suggests that the majority of the genomes of mammals and other complex organis Read More
-
-
-
MicroRNAs and Cardiac Conduction
Authors: M.V.G. Latronico and G. CondorelliHeart ion-channel function and expression are continuously being regulated on the basis of the hemodynamic state of the cardiovascular system, the neurohumoral milieu and the properties of the ongoing ionic fluxes. These homeostatic forces act through multiple mechanisms at transcriptional, translational and post-translational levels. Of clinical importance is the fact that with adverse stress these regulatory me Read More
-
-
-
Expression and Function of MicroRNAs in Heart Disease
Authors: Sadakatsu Ikeda and William T. PumicroRNAs (miRNAs) are powerful, recently recognized regulators of gene expression. miRNAs modulate virtually all aspects of cardiac biology, from cardiac specification and development to cardiomyocyte survival and hypertrophy. Expression profiling of experimental and human heart disease has shown that miRNA expression is altered in heart disease, and miRNA expression signatures may be useful biomarkers for he Read More
-
-
-
MicroRNA-21: From Cancer to Cardiovascular Disease
Authors: Virginija Jazbutyte and Thomas ThumMicroRNA-21 (miR-21) expression is activated in multiple types of cancers, such as breast, liver, brain, prostate, myometrial cancers but also in cardiovascular disease. MiR-21 regulates a plethora of target proteins which are involved in cellular survival, apoptosis and cell invasiveness. MiR-21 regulation is complex due to an own promoter that is target for various transcription factors and hormones. The consistent miR-21 over Read More
-
-
-
microRNA Regulation as a Therapeutic Strategy for Cardiovascular Disease
Authors: Rusty L. Montgomery and Eva van RooijMicroRNAs are small non-coding RNAs that regulate gene expression at the posttranscriptional level by either inhibiting mRNA translation or inducing mRNA degradation. These regulatory mechanisms occur in a sequence-specific manner through the direct binding of the microRNA to complementary reverse sequences in the 3' UTR of target mRNAs. The sequence-specific nature of microRNAs allows for the regulation Read More
-
-
-
Vascular microRNAs
Authors: Angelika Bonauer, Reinier A. Boon and Stefanie DimmelerMicroRNAs are endogenously expressed small non-coding RNAs that regulate gene expression on the posttranscriptional level. During the last years microRNAs have emerged as key regulators of several physiological and pathophysiological processes in the vascular wall. Endothelial cell functions and angiogenesis are critically regulated by microRNAs such as miR-126 and the miR-17-92 cluster in vitro and in vivo. Tumor angiogene Read More
-
-
-
MicroRNAs in Arterial Remodelling, Inflammation and Atherosclerosis
Authors: C. Weber, A. Schober and A. ZerneckeAtherosclerosis is now widely appreciated to represent a chronic inflammatory reaction of the vascular wall in response to dyslipidemia and endothelial distress involving the inflammatory recruitment of leukocytes and the activation of resident vascular cells. The proliferative response of smooth muscle cells critically contributes to arterial remodelling. As part of the inflammatory infiltrate, monocytes/macrophages, but als Read More
-
-
-
Potential Therapeutic Targets for Steroid-Resistant Asthma
Authors: Wan Wang, Jing Jing Li, Paul S. Foster, Philip M. Hansbro and Ming YangGlucocorticoids are the mainstay of asthma management and effectively treat acute exacerbations of asthma. However, a small subset of asthmatics, usually with severe asthma, respond poorly even to systemic administration of high-dose glucocorticoids and this condition is termed “steroid-resistant asthma”. This cohort, although small, accounts for ~50% of total health care cost for asthma. New investigations into Read More
-
-
-
Kisspeptin: A Critical Regulator of Puberty and Reproductive Function
Authors: Amir H. Sam and Waljit S. DhilloKisspeptin has emerged as a critical player in the initiation of puberty and reproductive function. In humans, inactivating mutations of the kisspeptin receptor result in hypogonadotrophic hypogonadism and kisspeptin receptor activating mutations cause precocious puberty. Kisspeptin potently stimulates the release of gonadotrophins predominantly through the release of gonadotrophin-releasing hormone (GnRH). Here we revi Read More
-
-
-
Serotonin-2 Receptor Agonists as Novel Ocular Hypotensive Agents and their Cellular and Molecular Mechanisms of Action: Novel Drug Targets for Glaucoma Treatment
More LessThe eye is innervated by numerous serotonergic nerves and serotonin (5-hydroxytryptamine; 5HT) is present in the aqueous humor of animal and human eyes. In an effort to delineate the role of the serotonergic system in modulating intraocular pressure (IOP) within the anterior segment of the eye, extensive topical ocular dosing studies were conducted with a variety of 5HT ligands and in various animal species. Even though Read More
-
-
-
Quantification of Intracellular Proteins and Monitoring Therapy Using Flow Cytometry
Authors: Richard L. Chang, Chen-Hsiung Yeh and Maher AlbitarHere we review phospho-specific, quantitative flow cytometry approach as a rapid and reliable tool for measuring intracellular signaling proteins with potential applications in monitoring efficacy of targeted therapy. The single cell, multiparameter nature of flow cytometry allows simultaneous investigation of specific cell type and the corresponding intracellular markers. Peripheral blood can be directly stained with surface mark Read More
-
-
-
Vascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Authors: Gang Niu and Xiaoyuan ChenNew blood vessel formation (angiogenesis) is fundamental to tumor growth, invasion, and metastatic dissemination. The vascular endothelial growth factor (VEGF) signaling pathway plays pivotal roles in regulating tumor angiogenesis. VEGF as a therapeutic target has been validated in various types of human cancers. Different agents including antibodies, aptamers, peptides, and small molecules have been extensively i Read More
-
-
-
Cholesterol, Alzheimer's Disease, Prion Disorders: A menage a trois?
Authors: Alessandra Pani, Antonella Mandas and Sandra DessiAberrant folded proteins are hallmarks of amyloidogenic diseases. Examples are Alzheimer's disease (AD) and prion-related disorders (PrD). These disorders, although clinically different, have the same underlying pathogenetic mechanism: an altered protein conformer with high β-sheet structure content: the amyloid beta peptide (Aβ) in the case of AD, and the aberrant prion protein, PrPsc in PrD. Although the molecular Read More
-
-
-
Potential Treatment of Cardiac Hypertrophy and Heart Failure by Inhibiting the Sarcolemmal Binding of Phospholipase Cβ1b
Authors: E.A. Woodcock, D.R. Grubb and P. IliadesHeart failure, the common end-point of many cardiac diseases, is a major contributor to mortality and morbidity and contributes considerably to health care costs. Current treatment regimens include β-adrenergic antagonists, angiotensin converting enzyme inhibitors, and inotropic agents are used by some patients. Studies in experimental animals have demonstrated that inhibition of signaling pathways downstream of the Read More
-
Volumes & issues
-
Volume 26 (2025)
-
Volume 25 (2024)
-
Volume 24 (2023)
-
Volume 23 (2022)
-
Volume 22 (2021)
-
Volume 21 (2020)
-
Volume 20 (2019)
-
Volume 19 (2018)
-
Volume 18 (2017)
-
Volume 17 (2016)
-
Volume 16 (2015)
-
Volume 15 (2014)
-
Volume 14 (2013)
-
Volume 13 (2012)
-
Volume 12 (2011)
-
Volume 11 (2010)
-
Volume 10 (2009)
-
Volume 9 (2008)
-
Volume 8 (2007)
-
Volume 7 (2006)
-
Volume 6 (2005)
-
Volume 5 (2004)
-
Volume 4 (2003)
-
Volume 3 (2002)
-
Volume 2 (2001)
-
Volume 1 (2000)
Most Read This Month
Article
content/journals/cdt
Journal
10
5
false
en
